Can CBG Or CBN Cannabinoids Reduce Dystonic Spasms? 

Current NHS and NICE guidance confirms there is no clinical evidence that CBG (cannabigerol) or CBN (cannabinol) can reduce dystonic spasms in humans. According to NICE Guidance NG144, cannabis-based medicinal products are currently approved only for specific conditions such as multiple-sclerosis-related spasticity (Sativex) and treatment-resistant epilepsy (Epidyolex). Dystonia is not an approved indication for any cannabis-based medicine on the NHS. 

What Current NHS And NICE Guidance Says 

According to NHS England’s guidance on cannabis-based products for medicinal use, only hospital specialists registered with the General Medical Council can prescribe these treatments. Approved use remains restricted to epilepsy and multiple sclerosis-related spasticity, and not dystonia. 

The NHS Medical Cannabis overview further explains that while cannabinoids like THC and CBD have recognised roles in these conditions, other cannabinoids such as CBG or CBN are not licensed for clinical use in the UK. 

What Research Says About CBG 

A 2024 review in Molecules reported that CBG demonstrated neuroprotective and anti-inflammatory effects in laboratory and animal models of neurodegenerative diseases. Researchers found that CBG interacts with CB2 and TRP receptors, which may help regulate nerve cell inflammation and muscle tone. 

Despite these promising mechanisms, the evidence remains limited to preclinical studies. There are no human clinical trials assessing CBG for dystonia or spasticity. 

What Research Says About CBN 

Similarly, emerging studies on CBN suggest potential benefits for neuronal stability. A 2024 Cells study found that CBN influenced calcium and potassium ion channels in motor neuron-like cells, and a 2025 mouse study reported improved synaptic energy efficiency and mitochondrial performance. 

However, like CBG, these findings are early and experimental. No published trials have evaluated CBN for muscle contractions or dystonia in people. 

THC And CBD: The Established Evidence 

Unlike CBG or CBN, the combination of THC and CBD in Sativex has moderate clinical evidence for reducing muscle stiffness in multiple sclerosis.  

According to a 2022 Cochrane Review, nabiximols (THC:CBD) improved perceived spasticity compared to placebo. Yet, NICE has stated this evidence cannot be generalised to dystonia or other movement disorders in its Guidance NG144 on cannabis-based medicinal products. 

The Clinical Bottom Line 

• NHS and NICE do not recommend CBG or CBN for dystonia or any movement disorder. 

• No human clinical trials currently support their use for dystonic spasms. 

• Preclinical data show possible neuroprotective and ion-channel effects, but these findings are limited to laboratory studies. 

• THC:CBD (Sativex) remains the only cannabinoid combination with licensed use for spasticity, not dystonia. 

• Further controlled research is required before minor cannabinoids can be considered in movement disorder care. 

Safe Next Steps 

For individuals interested in understanding regulated cannabinoid access in the UK, providers like AlleviMed help patients and clinicians navigate eligibility and prescribing frameworks for medical cannabis. These services operate within UK legal standards and are not substitutes for NHS or specialist neurological care. 

Summary Takeaway 

As of 2025, CBG and CBN remain unlicensed and experimental for dystonia. The strongest evidence in cannabinoid therapy still relates to THC and CBD combinations for multiple sclerosis and epilepsy. Anyone considering cannabinoid treatment for movement symptoms should speak with a specialist neurologist and rely only on NHS-approved or MHRA-licensed products.